Exchange: NASDAQ·Updated 04:15 PM EST
CRVS logo

CRVS Corvus Pharmaceuticals Inc

$9.67
$0.34
(3.40%)
Today
Closed $9.67
$0.00
(0.00%)
After Hours
Reported EarningsNov 5
Mkt Cap$844.37M
Vol927,137.00

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.
39

Bearish Sentiment

How do you feel about CRVS?

tradingjunk321
$CRVS Arcara might be sleeping behind the desk, but atleast he bought some stock in last 3 days! Form 4 below!
1
8
biotech_loser
$CRVS it’s a treat to hear Miller. His earnings calls are like a professor giving a lecture to its students. So clear - point by point.
8
hmandude
$CRVS Nothing new on the presentation today. But it again crystallizes the plan of multiple readouts in 2027 (AD, PTCL, HS) and then asthma at some point. Cash until 2028. They likely decided on a shorter HS POC study in order to get data in 2027. I still believe the plan is to get all this data in 2027 and then listen to the highest bids by 2028.
7
TheGunnerAB
$CRVS 650 of January 2028 calls were bought already, first 30 minutes of trading, average price of $5, so total premium paid is $325K.
1
4
tradingjunk321
$CRVS Miller " I want to better than Dupi". It's gonna happen under another large Pharma name after acquiring CRVS! Moore to come!
5
tradingjunk321
$CRVS 4 orals out there, the best part! We have a CEO that is fully committed, 3 years pay forgone in lieu of cash for stock (89%), 76ish years old (gonna sell at some point to cash in on his 6 million + shares). And the best point is the other 3 competitors are a market cap of minimum $8.5 billion and higher, when CRVS is just under $900 million! Miller come on give us 3-4 Billion+
6
hzhou088
$CRVS Abstract Analysis: 2. The most important findings A. Abnormal T-cell proliferation was reduced ALPS is characterized by accumulation of double-negative T cells (DNTs), specifically CD3+, CD4−, CD8− cells. At baseline, Ki67 expression in DNTs was significantly higher than in normal controls. Baseline Ki67 positivity was 30%, 68%, and 45% in the three patients (p = 0.0002 versus normal controls). Patients 2 and 3 experienced reductions in circulating Ki67-positive DNTs of 20% and 75%, respectively. Ki67 is a marker of cellular proliferation. These reductions are consistent with soquelitinib suppressing abnormal proliferative activity in this cell population. The abstract demonstrates a reduction in proliferating DNTs, not necessarily elimination of the underlying genetically defective lymphocytes. It also reports no changes in total circulating CD4 or CD8 cells.
6
Jellysquid1
$CRVS I Got The Sign To BUY!…. I was in Philadelphia Today And right across my hotel Was this building……
1
2
abc12332
$CRVS We could be days away from getting ALPS data. The abstracts for the regular sessions for the ASH meeting will be released on 11/4/26. This meeting is in December and times perfectly with when the data is anticipated. It would also time perfectly with the conference call on 11/5/26. On the other hand, the abstract would have been due in August and it may not have been ready. Latebreaking abstracts will be released 12/7 but this data wouldn’t fit the criteria so LBing is highly unlikely. 11/4 is our best chance.
5
ILikeDaStocks
$CRVS I asked AI why Saudi Arabia has a 4% rate of hidradenitis suppurative when compared to the rest of the world at 1%. The answer follows: • "Active Screening and Underdiagnosis Elsewhere: Much of the high rate identified in recent Saudi studies (such as the GHiSA project in Riyadh) comes from active clinical examination of general populations rather than relying solely on previously reported hospital visits. Researchers note that historical global numbers reflect severe underdiagnosis, and proactive screening reveals cases that previously went unrecorded." So, the prevalence and need for effective treatment is great and the market may be significantly larger than most are assuming.
5
Medusana
$CRVS The drug is also being developed for atopic dermatitis and hidradenitis suppurativa. Success in inflammatory diseases could give CRVS opportunities beyond cancer!!
5
VISIUM
$CRVS uh oh kymr. Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader
4
Jellysquid1
$CRVS Just Listened To IOVA Conference Call, Fred was Terrible! He read All his data from a paper and Rushed everything. Also they Had problems with hearing Analyst speaking. If you want to hear a Real Professional speak, listen On Nov 5th To RICHARD MILLER !
4
VISIUM
$CRVS Naturally, Corvus's biggest catalyst year has to coincide with the market's scheduled apocalypse. Wouldn't have it any other way.
2
Mr_Predicto
$CRVS Well, well, well, what is this I see? Signs of life? Maybe a single cell amoeba? Sure, it is getting some lift from the overall market and general bio sector, but it doesn't always go up in kind. Is this a change in sentiment? Is it simple repositioning ahead of anticipated trial results? Should I short this again? Should I go long this time? More questions than answers at the moment, but I can say it is back on my radar. Prediction: Crystal ball is telling me to try again later. (still neutral).
3
dwsrph1
$CRVS I will tell all of you. SQL is a game changer. You that doubt will lose your money. If you disagree fine! Every time SQL unlocks one door there is 3 more the key fits. You can down me you can say I’m stupid I don’t care what you say. I have a lot of cash here and I am not going to lose.
3
GaryGherkins
$CRVS that’s it, we got the buyout offer. Signed sealed & delivered. Novartis is currently the stalking horse, their desperate to buyout a company they haven’t even partnered with
3
Gaia2
$CRVS The shorts should start buying to cover soon. In the midst of breaking news, that should be fun to watch.
3
Gaia2
$CRVS When CRVS makes its next move up, there won't be a small pop, there will be an explosion! It's coming!
3
Telleast_
$CRVS Per AI (artifical intelligence), it may be worth pondering the the information in the screenshot below derived from AI, (while taking into account multiple upcoming potential catalysts between now and throughout the entire calendar year 2027). None of the foregoing is financial advice or to be in any way construed as financial advice.
2

Advertisement|Remove ads.